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Abstract 
NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine 
potency and safety testing methods and to identify opportunities to advance new and improved methods that can further reduce, 
refine, and replace animal use. Topics were addressed in detail by speakers and workshop participants and are reported in a series
of six reports. This workshop report, the third in the series, addresses methods and strategies for human vaccine potency testing
that can refine animal use to lessen pain and distress, improve animal welfare, and reduce animal use. Workshop participants 
agreed that the following potency tests for human vaccines should have the highest priority for development of reduction and/or
refinement methods: (1) potency tests for vaccines that are most commonly used, (2) potency tests that require the largest number
of animals, (3) potency tests that cause severe animal pain and distress, (4) potency tests where the knowledge base of each 
antigen is advanced, and (5) potency tests for which alternative methods already exist or are in development. Based on these 
criteria, the highest-priority human vaccines were identified as diphtheria and tetanus vaccines, pertussis vaccines (whole cell and 
acellular), rabies vaccine, anthrax vaccine, and complex combination vaccines (containing diphtheria, tetanus, and pertussis 
together with other antigens such as IPV, Hib, and HepB). For successful implementation of reduction and refinement 
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alternatives, further research is required into the development and broader use of humane endpoints, serological potency 
methods, and approaches that would reduce the number of animals used in currently approved potency assays. Because the 
workshop focused on both human and veterinary vaccines, workshop participants also recommended that human vaccine potency 
testing methods for rabies and tetanus be reviewed for their potential application to the corresponding veterinary vaccines. 
Participants agreed that achieving broader acceptance and use of alternative methods, requires that the general principles and 
procedures for the validation of alternative methods for vaccines be standardized/harmonized internationally. The research, 
development, validation, and harmonization activities recommended at this workshop are expected to lead to new reduction 
and/or refinement of animal use in human vaccine potency testing methods and more widespread adoption of existing methods 
that can reduce animal use and improve animal welfare while ensuring the continued safety and efficacy of human vaccines. 
© 2011 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of the National Toxicology Program 
Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) 
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1. Introduction 
Vaccines contribute to improved human and animal health and welfare by preventing diseases and deaths caused 
by infectious agents. However, the testing necessary to ensure vaccine effectiveness and safety can involve large 
numbers of animals and significant pain and distress. In the United States, the Interagency Coordinating Committee 
on the Validation of Alternative Methods (ICCVAM) and the National Toxicology Program Interagency Center for 
the Evaluation of Alternative Toxicological Methods (NICEATM) promote the scientific validation and regulatory 
acceptance of test methods that accurately assess the safety of chemicals and products while reducing, refining (less 
or no pain and distress), and replacing animal use. Accordingly, NICEATM and ICCVAM recently identified 
vaccine potency and safety testing as one of their four highest priorities [1].
ICCVAM is an interagency committee of Federal agencies that is charged by law with evaluating new, revised, 
and alternative test methods with regulatory applicability. ICCVAM members represent 15 U.S. Federal regulatory 
and research agencies that require, use, generate, or disseminate safety testing data. These include the U.S. 
Department of Agriculture (USDA), which regulates veterinary vaccines, and the U.S. Food and Drug 
Administration (FDA), which regulates human vaccines. ICCVAM is a permanent interagency committee of the 
National Institute of Environmental Health Sciences (NIEHS) under NICEATM. NICEATM administers ICCVAM, 
provides scientific and operational support for ICCVAM-related activities, and conducts validation studies on 
promising new safety testing methods. NICEATM and ICCVAM serve a critical public health role in translating 
research advances from the bench into standardized safety testing methods that can be used in regulatory practice to 
prevent disease and injury. 
To promote and advance the development and use of scientifically valid alternative methods for human and 
veterinary vaccine testing, NICEATM and ICCVAM organized the International Workshop on Alternative Methods 
to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency and Safety Testing: State of the Science and 
Future Directions. The workshop was held at the National Institutes of Health in Bethesda, Maryland, on September 
14–16, 2010. It was organized in conjunction with the European Centre for the Validation of Alternative Methods 
(ECVAM), the Japanese Center for the Validation of Alternative Methods (JaCVAM), and Health Canada. 
The workshop addressed the state of the science and developed recommendations for future progress in three 
major areas for human and veterinary vaccines: (1) in vitro replacement methods for potency testing; (2) reduction 
and refinement methods for potency testing; and (3) reduction, refinement, and replacement methods for vaccine 
safety testing [2]. Reports were prepared for each of the three topics for human vaccines and for each of the three 
topics for veterinary vaccines [3, 4, 5, 6, 7, 8]. This report addresses methods and strategies for the reduction and 
refinement of animal use for potency testing of human vaccines.  
Three major strategies for reduction and refinement are discussed. The first is the application of earlier humane 
endpoints to reduce the duration and severity of pain and distress that can occur during lethal challenge testing. 
Challenge testing is conducted to determine the amount of vaccine that will protect animals from infection with live 
agents (virus or bacteria) or challenge with toxin. Inadequately protected animals often develop clinical disease or 
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die. The second strategy is the development and use of serological methods that can eliminate the need for direct 
challenge testing. In serological methods, the amount of protective antibody produced is measured and serves as an 
indicator of vaccine potency. The procedure is significantly less severe than challenge methods. The final strategy 
involves the application of methods and approaches that may reduce the number of animals used in each test.  
2. Goals and organization of the workshop 
The goals of the international workshop were to (1) identify and promote the implementation of currently 
available and accepted alternative methods that can reduce, refine, and replace the use of animals in human and 
veterinary vaccine potency and safety testing; (2) review the state of the science of alternative methods and identify 
knowledge and data gaps that need to be addressed; and (3) identify and prioritize research, development, and 
validation efforts needed to address these gaps in order to advance alternative methods that will also ensure 
continued protection of human and animal health. 
The workshop was organized with four plenary sessions and three breakout group sessions. In the breakout 
sessions, workshop participants were asked to do the following: 
x Identify criteria for prioritization of vaccines for future alternative test method development and prioritize 
vaccines using the identified criteria 
x Review the current state of the science of alternative methods and discuss ways to promote the implementation of 
available methods 
x Identify knowledge and data gaps that need to be addressed 
x Identify and prioritize research, development, and validation efforts needed to address these gaps to advance 
alternative methods while ensuring continued protection of human and animal health 
The workshop opened with a plenary session in which expert scientists and regulatory authorities from the United 
States, Europe, Japan, and Canada outlined the importance of vaccines to human and animal health [9, 10] and 
described national and international regulatory testing requirements for human and veterinary vaccines [2, 11, 12, 
13, 14, 15, 16]. Authorities emphasized that, after licensing of a vaccine, testing must ensure that each subsequent 
production lot is safe and sufficiently potent to generate a protective immune response in people or animals [11, 12]. 
The second plenary session addressed methods that have been accepted and methods that are in development that 
do not require the use of animals for assessing the potency of vaccines [17, 18, 19, 20]. This was followed by 
breakout sessions to discuss the state of the science and recommendations for future progress for in vitro potency 
tests for human and veterinary vaccines [3, 4].
The third plenary session addressed (1) potency testing methods that refine procedures to avoid or lessen pain and 
distress by incorporating earlier humane endpoints or by using antibody quantification tests instead of challenge 
tests and (2) methods and approaches that reduce the number of animals required for each test [21, 22, 23, 24, 25, 
26, 27]. Breakout groups then discussed the state of the science and developed recommendations for future progress. 
Workshop recommendations to advance the use and development of alternative methods that can reduce and refine 
animal use for potency testing of human vaccines are provided in this paper. Recommendations for veterinary 
vaccines are available elsewhere in these proceedings [6]. 
The final plenary session addressed methods and approaches for reducing, refining, and replacing animal use for 
assessing the safety of production lots of human and veterinary vaccines [11, 28, 29, 30]. Breakout groups for 
human and veterinary vaccines then discussed the state of the science and developed recommendations for 
advancing alternative methods for vaccine safety testing [7, 8].
3. Requirements for human vaccine potency testing
Human vaccines save lives, prevent disease and morbidity, and represent a critical tool for successful and cost-
saving health interventions. For example, for each U.S. birth cohort that receives a series of vaccines against various 
diseases (e.g., diphtheria, tetanus, pertussis, measles, mumps, rubella, polio), an estimated 14 million disease 
episodes and 33,000 premature deaths are prevented [10]. These vaccinations are estimated to save 43 billion dollars 
in medical and societal costs [10, 31].  
Many variables complicate animal testing (e.g., experimental variation, costs, animal numbers, pain, distress). 
The complex nature of animal testing has prompted many regulatory agencies to actively encourage the evaluation, 
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development, and implementation of novel approaches that reduce, refine, and replace (3Rs) the use of animals in 
testing the potency and safety of vaccines for product release [19, 32].
The U.S. Public Health Service Act [33] and certain sections of the U.S. Food, Drug and Cosmetic Act [34] give 
the FDA the authority to regulate vaccines. Section 351 of the Public Health Service Act states that the approval of a 
biologics license is based on the demonstration of product safety, purity, and potency and assurance that the facility 
for manufacture, processing, and packaging meets the standards to ensure that product released for distribution is 
safe, pure, and potent. The regulatory definitions of safety, purity, and potency are detailed in Title 21 of the U.S. 
Code of Federal Regulations (Section 600.3) [35]. Testing methodology and validation must be included in the 
biologics license application. Safety and potency testing may be performed on the final bulk sample or final 
container sample and may consist of either in vivo or in vitro tests or both. To change a potency or safety test after 
licensing requires a supplement to the license with rationale and data to support the alternative (potency and safety) 
or demonstration of lack of need (safety).  
The Center for Biologics Evaluation and Research (CBER) has an active research program that evaluates, 
develops, and integrates novel scientific technologies for use in product regulation, including the development and 
analysis of approaches that reduce, refine, and replace the use of animals. CBER encourages the development of 
these alternative methods for vaccine potency and safety testing with appropriate relevance, supporting data, and test 
method validation. 
4. Prioritizing vaccine potency tests for future refinement and reduction efforts 
Potency testing methods for several human vaccines still test animals (Table 1). Therefore, the development and 
subsequent validation of alternative reduction and refinement assays for any human vaccine have the potential to 
significantly reduce animal numbers and the associated pain and distress during testing. To prioritize human 
vaccines for further development and validation of alternative tests, workshop participants established the following 
criteria:
x Vaccines that are most commonly used  
x Vaccines for which existing methods require the largest number of animals per test  
x Vaccines for which current potency tests cause severe animal pain and distress 
x Vaccines for which the knowledge base of each antigen (including antigenic properties, antigenic potency, 
important, epitopes, etc.) is advanced, allowing determination of those antigens that are most amenable to the 
development of alternative tests 
x Vaccines for which alternative tests are in development or already exist (e.g., in vitro assays using Vero cells for 
diphtheria vaccine)
Workshop participants identified the following vaccines as the highest priorities for additional research, 
development, and validation efforts:  
x Diphtheria and tetanus toxoids (due to [1] requirement for toxin challenge; [2] use of large numbers of animals; 
and [3] the fact that neutralizing antibody production is the primary correlate of protection, allowing serological 
methods to be developed)  
x Whole cell pertussis vaccines (due to the severity of the challenge test)  
x Rabies vaccines (due to the severity and inherent variability of the challenge test)
x Anthrax vaccines (due to the severity of the challenge test) 
x Combination vaccines (due to the large numbers of animals used to test each vaccine and the possibility of 
developing a single serological assay for multiple components in the same vaccine, including diphtheria, tetanus, 
and acellular pertussis antigens)  
The rationale for the selection of the vaccines listed above was based primarily on the number of animals 
currently used to document potency, the number of lots produced each year, and the severity of pain and distress in 
the current challenge tests. 
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Table 1: Examples of human vaccine potency assays that incorporate immunization and in vitro antibody 













Tetanus toxoid vaccine 
and tetanus component 
in combined vaccines 
(Clostridium tetani)
Single-dilution immunization 
and serologyb, c –in vitro
toxin-binding inhibition 
(ToBIb, c), indirect ELISAb, c 
Dobbelaer et al. 1997 
[36]; Ph. Eur. 2.7.8. 
Assay of tetanus vaccine 
(adsorbed) [37]; WHO 
TRS 927, 2003 [38] 
Guinea pig or mouse 
lethal challenge test 
U.S. Minimum 
Requirements, 1952 
[39]; Ph. Eur. 2.7.8 
[37]; WHO TRS 
927, 2003 [38] 
Diphtheria toxoid 
vaccine and diphtheria 





and Serology– ELISA or 
Vero Cell Assayb, c
Ph. Eur. 2.7.6 Assay of 
diphtheria vaccine 
(adsorbed) [40]; WHO 
TRS 927, 2003 [38] 




[41]; Ph. Eur. 2.7.6 
[40]; WHO TRS 
927, 2003 [38] 
Acellular pertussis 




Immunization (mice) and 
serologya, b, c 
ELISA
Ph. Eur. Monograph 1356 
[42] and 1595 [43]; 





2006 [46]; WHO TRS 
878, 1998 [47] 
Multiple-dilution
mouse serologyc
Ph. Eur. 2.7.7 [45] 
Rabies vaccine; 
(Lyssavirus rabies)
Immunization (mice) and 
Serologyb, c 
Ph. Eur. Monograph 216 







aAccepted by U.S. regulatory authorities. 
bPublished in the European Pharmacopoeia.  
cWHO Technical Report Series number and year of publication. 
5. Human vaccine potency testing: using humane endpoints to refine animal use
5.1. State of the science 
Assays to measure the potency of vaccines are frequently based on an immunization-challenge procedure in 
laboratory animals. While replacing animal use is the ultimate objective for developing alternative vaccine potency 
tests, an immediate transition from an in vivo test to a non-animal test method is technically difficult and, where 
possible, time consuming. However, interim success toward improving animal welfare in vaccine potency testing 
may be accomplished by developing refinement alternatives that reduce the pain and distress that may be 
experienced by the animals. For example, humane endpoints are criteria that can be used as the basis for ending a 
test procedure early in order to avoid further pain and distress. Ideally, humane endpoints may be used to end a 
procedure before the onset of animal pain and distress [37, 51, 52]. However, the use of earlier, more humane 
endpoints must allow the specific testing objectives to be met. With the development of earlier, more humane 
criteria for detecting infection and/or toxicity it is possible to minimize the extent of animal pain and distress during 
in vivo immunization–challenge procedures before they are humanely euthanized.  
The use of humane endpoints to reduce animal pain and distress is reflected in the regulatory guidance documents 
and/or legislation of relevant agencies in numerous regions and countries worldwide. Examples include the 
European Directorate for the Quality of Medicines & HealthCare (EDQM) and the associated European 
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Pharmacopoeia (Ph. Eur.) and the U.S. Code of Federal Regulations [51, 52, 53, 54, 55, 56, 57]. The adoption of 
scientifically valid humane endpoints whenever possible is also a fundamental principle of the U.S. Public Health 
Service Policy on Humane Care and Use of Laboratory Animals [58], as well as existing statutory requirements in 
the United States [58] and the EU [48]. Specific legislation has been adopted to use humane endpoints during 
vaccine potency testing procedures [55, 56]. 
The use of humane endpoints during in vivo testing of biological products is required in the United States for 
veterinary vaccines [56] and for both human and veterinary vaccines in Europe [59, 60]. Although there have been 
significant advances in the identification of early humane endpoints in human vaccine potency testing, more work 
remains in identifying and validating humane endpoints for specific disease processes. For example, the use of 
humane endpoints during the potency testing of human inactivated rabies, tetanus, and diphtheria vaccines (Table 2)
has been widely accepted by regulatory authorities around the world, including the EDQM and the WHO [61, 38, 
49]. Clinical signs such as a clear reduction in body weight, or slow and circular movements followed by cramps 
and paralysis, are considered the first neurological symptoms of rabies and now serve as reliable indicators for 
humane endpoints [62]. Additional examples of approved humane endpoints include, paresis of the injected hind 
limb of mice and erythema observed following intradermal challenge in guinea pigs for tetanus and diphtheria 
vaccine potency tests, respectively. 
Hendriksen and colleagues (1999) [63] evaluated potential humane endpoints during the potency assay of whole 
cell pertussis vaccine. A loss of muscle coordination and a decrease in body temperature were identified as useful 
humane endpoints. However, these early endpoints have yet to achieve broad regulatory acceptance, and research 
continues toward furthering the refinement alternatives for whole cell pertussis vaccine potency testing. 






Traditional Test Procedure 
for Which the Alternative 








paresisa, b, c 
Ph. Eur. Monograph 
216 [48]; WHO TRS 
941, 2007 [49] 
Mouse multiple-dilution 
lethal challenge test
Seligmann 1973 [50] 
Tetanus toxoid vaccine 
(Clostridium tetani) and 
tetanus component in 
combined vaccines  
Toxin-injected 
hind leg paresisa, b
Ph. Eur. 2.7.8. Assay of 
tetanus vaccine 
(adsorbed) [37]; WHO 
TRS 927, 2003 [38] 
Guinea pig or mouse lethal 
challenge test 
Ph. Eur. 2.7.8. Assay of 
tetanus vaccine (adsorbed) 
[37]; WHO TRS 927, 
2003 [38] 









Ph. Eur. 2.7.6 Assay of 
diphtheria vaccine 
(adsorbed) [40]; WHO 
TRS 927, Annex 5, 
2003 [38] 
Guinea pig lethal challenge 
test
Ph. Eur. 2.7.6 Assay of 
diphtheria vaccine 
(adsorbed) [40]; WHO 
TRS 927, 2003 [38] 
aPublished in the European Pharmacopoeia.  
bWHO Technical Report Series number and year of publication. 
c Accepted by U.S. regulatory authorities.
5.2. Knowledge gaps and priority research, development, and validation activities 
Workshop participants discussed current knowledge and data gaps. They focused on the research needed to fill 
these gaps to further advance the development, validation, and implementation of potency tests that incorporate 
humane endpoints. 
Some current vaccine potency tests involve an initial immunization followed by either (1) direct challenge with 
an infective organism or toxin in vivo or (2) an in vivo toxin neutralization assay in a second group of animals using 
antisera collected from the immunized animals. In both tests, animals are subjected to considerable pain and distress 
before they are considered moribund or die. The development of methods that can detect earlier signs of infection, 
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or toxicity markers that accurately predict death, would reduce the extent to which animals are in pain before they 
can be humanely euthanized. These signs may include the following: (1) paralysis or dehydration; (2) erythema; 
(3) pathophysiological parameters such as body temperature, body weight, or tachycardia; and (4) behavioral 
parameters such as stereotypic behavior, self-mutilation, or aggression [25]. Workshop participants agreed that there 
was no logical or scientific rationale for requiring death as an endpoint in vaccine challenge potency testing. 
However, they emphasized the importance of ensuring that any earlier signs are accurately predictive of death, given 
the potential impact on potency assessment. Among the most important data and knowledge gaps identified by the 
participants were: 
x Identifying humane endpoints for vaccines for which suitable serology methods do not exist or would not help 
predict potency because protection is not predominately antibody mediated  
x Recognizing clinical signs at the institutional level, noting the need for training and standardization of classical 
signs of humane endpoints 
Workshop participants called for comprehensive training and routine systematic collection and evaluation of all 
clinical signs that occur during a challenge test. They recognized the need for detailed institutional protocols and 
guidance documents instead of a strict general protocol as the best ways to facilitate identification and validation of 
humane endpoints. Also, identifying and validating humane endpoints during the development/validation of 
serological methods was considered the most efficient and expeditious means toward implementation of humane 
endpoints.  
The workshop participants also discussed practical issues. These included (1) ensuring that observation intervals 
are consistent and sufficiently narrow to allow identification of clinical signs; (2) recognizing when early 
termination of the test is not practical due to a rapid progression of pathology; and (3) considering new technologies 
for monitoring activity, body temperature, body weight, etc., remotely (sensory cages) to avoid stress from human 
contact. However, participants also recognized the limitations associated with using new technologies, such as 
expense of equipment, strict monitoring/calibration requirements, and training requirements. 
6. Human vaccine potency testing: using serological methods to refine animal use 
6.1. State of the science 
As shown in Table 1, many of the high-priority vaccines that currently use animals in challenge testing already 
have serological methods available or in development. In these test methods, the amount of a specific antibody in 
the blood of immunized animals is used as surrogate for demonstrating protection against challenge by the relevant 
pathogen or toxin. Clearly, these vaccines should be targeted for further validation efforts because they are most 
likely to lead to successful implementation of refinement alternatives. Some of the earliest and most widely accepted 
examples of using serological methods to measure a specific antibody response in immunized animals include the 
enzyme-linked immunosorbent assay (ELISA) and toxin-binding inhibition (ToBI) test assay in animals immunized 
with tetanus toxoid [64].  
An interlaboratory validation study to evaluate the suitability of in vitro serological assay systems for the 
assessment of the potency of tetanus toxoid in single and multicomponent veterinary vaccines was reported in 1994 
[65]. The study evaluated the ELISA; the ToBI; and the passive hemagglutination (HA) test, an agglutination assay 
in which red blood cells are used to absorb soluble antigen on their surface and then agglutinate in the presence of 
antiserum specific for the absorbed antigen. It was concluded that the ELISA and the ToBi assay were both suitably 
validated methods, while the HA test required further standardization before use. The Ph. Eur. and the World Health 
Organization (WHO) have accepted the ELISA and the ToBI assay for use with serological assays for potency 
measurements of both human and veterinary tetanus toxoid vaccines. 
When the mechanism that protects against a virulent organism or toxin is based on humoral immunity, the use of 
serological approaches offers certain advantages. Some regulatory agencies accept serological approaches for the 
measurement of potency for a number of vaccines, including those for diphtheria, acellular pertussis, and rabies (for 
veterinary use) (Table 1), as well as a number of clostridial and leptospiral (for veterinary use) species [66]. Such 
approaches may be particularly beneficial (in terms of animal welfare) for testing of combined vaccines. In addition 
to the refinement of the procedure that is obtained when serology is used instead of challenge, there is the possibility 
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of measuring the antigen response to more than one component in the vaccine in the same group of animals. This 
may ultimately remove the requirement to perform a separate potency test for each vaccine component, thereby 
significantly reducing the number of animals required for potency testing of some products. 
6.2. Knowledge gaps and priority research, development, and validation activities 
Workshop participants identified several knowledge and data gaps associated with the development, validation, 
and implementation of serological methods, including the following: 
x To promote broader use of alternative methods, a comprehensive review and assessment of validated refinements 
that are approved by some authorities for toxoids should be completed and made widely available (recognizing 
that the proprietary nature of these methods may make this difficult). 
x Further research and validation is necessary to allow broader use of the Vero cell assay and ELISA for measuring 
responses to diphtheria toxoid. 
x Further research is necessary to allow broader use of the ELISA and ToBI for measuring antibodies to tetanus 
toxoid. Participants noted that the forthcoming WHO manual for DTP testing would provide additional guidance. 
x Regulatory authorities encourage alternatives, but it is the manufacturers’ responsibility to demonstrate a valid 
method for their specific product. The effort, time, and expense of this testing was recognized as a major hurdle. 
Krämer and colleagues [67] demonstrated the wider transferability and reliability of using mean neutralizing 
antibody titers (as determined by the rapid fluorescent focus inhibition test [RFFIT]) as a potency assay for 
inactivated rabies vaccines for veterinary use. Based on this study, the authors suggested that the RFFIT could be 
used for inactivated rabies vaccine potency testing. While it is now recognized by the WHO [49] as a valid 
alternative test method, workshop participants emphasized that further research and validation efforts are necessary 
for the RFFIT to gain broader acceptance for human rabies vaccine potency testing.
Participants also recommended continued research and validation of the immunogenicity test to measure antibody 
response to anthrax vaccine. This test could provide a substitute for the current active protection potency test. 
Current research focuses on determining the suitability of either an ELISA [68] or an in vitro toxin neutralization 
assay (TNA) to measure the antibody response in immunized mice [24]. These assays have the following advantages 
over the current immunization–challenge assay that uses guinea pigs: 
x These assays avoid challenge with virulent B. anthracis
x They are less costly, requiring fewer, less expensive animals than the current test 
x They are more humane and cause less animal pain and distress 
Estimates of the quantity of antibodies to the protective antigen (PA) obtained by ELISA and TNA are correlated, 
but they are not interchangeable because a precise prediction of TNA estimates from ELISA estimates could not be 
obtained. In addition, antibody estimates obtained by TNA are typically lower than those obtained by ELISA. The 
basis for this difference is not known but may be related to the fact that neutralizing antibodies represent only a 
fraction of the antibodies that bind PA. Further research will be needed to address these important issues [24] and 
experience with similar studies performed with Diphtheria vaccines may be relevant [69, 70, 71]. 
7. Human vaccine potency testing: strategies to reduce animal use 
7.1. State of the science 
The number of animals used in potency determinations can be reduced in several ways. Two obvious and 
immediate ways would be to simply reduce the number of animals used per dose of the vaccine and/or to reduce the 
number of doses used. Each would require a determination that adequate statistical power is maintained.  
The EDQM (Ph. Eur.) and the WHO recommend that, after sufficient experience with the mouse rabies potency 
challenge test (NIH test), a manufacturer can use a single-dilution challenge assay for inactivated veterinary rabies 
vaccine potency testing [48, 49]. Single-dilution testing for human rabies vaccines is still at the experimental stage.  
Additional attempts have been made to reduce the number of mice used at each dilution in the mouse rabies 
potency challenge test for inactivated human rabies vaccine. The Brazilian National Control Laboratory conducted 
retrospective evaluation of potency test results and concluded that the results from reducing the number of mice per 
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dilution from 18 to 9 in the mouse rabies potency challenge test did not adversely impact the results of the test [72]. 
Neither the single-dilution assay nor reduction in the number of mice per dilution has gained widespread regulatory 
acceptance to date. Similar reduction schemes for potency testing of diphtheria and tetanus vaccines are 
recommended by the WHO and the EDQM (Ph. Eur.) [37, 38, 40]. 
The use of serological methods for vaccine potency testing may also lead to a significant reduction in animal use 
in addition to the refinement benefits that this approach can provide.  Combination vaccines are particularly 
important because of their increasingly expanded use, a trend that is expected to continue as a means to reduce the 
number of vaccinations a child receives [10]. These vaccines present the unique challenge of the need for potency 
estimates for each of the active components. For example, potency testing for the DTaP combination vaccine 
typically requires separate tests for each of the major components (diphtheria, tetanus, and acellular pertussis). 
Therefore, combining the individual potency procedures into one serological test for multivalent vaccines would 
have an immediate and significant impact on reducing animal use. 
7.2. Knowledge gaps and priority research, development, and validation activities 
Workshop participants identified several key knowledge and data gaps associated with the development, 
validation, and implementation of vaccine potency reduction methods including:
x Knowledge of the causes of variability of potency estimates derived from active protection (particular note was 
made of the highly variable mouse potency challenge test for inactivated rabies vaccine) and serological assays is 
needed
x Knowledge of the causes of invalid assays for some vaccines that often lead to a requirement for repeat testing is 
required 
Although there would often be product-specific activities, which may not have broad applicability, workshop 
participants also suggested a number of activities to address these knowledge gaps: 
x Identifying the sources of variation in the current methods and ways to reduce or eliminate these sources of 
variation  
x Recalculating the minimum number of animals required to maintain statistical power and test validity 
x Encouraging those countries that use the full (3-dilution) test for diphtheria and tetanus potency testing to reduce 
the number of vaccine dilutions used  
x Investigating the use of homologous (product-specific) reference preparations to reduce variability/improve 
precision 
8. Achieving broader acceptance and use of currently available reduction and refinement methods for human 
vaccines
An early, critical step in obtaining broader acceptance and use of reduction and/or refinement approaches in 
vaccine potency testing is to harmonize acceptance criteria for vaccines and obtain recognition of test results among 
international regulatory authorities. This could lead to the elimination of any requirement for an importing national 
control laboratory (NCL) to test vaccines before release for sale (note; US regulations do not require FDA to test 
vaccines before release for sale). Elimination of this requirement could significantly reduce animal use. Similarly, 
clear guidance on the requirements and general principles and procedures for validation of alternative methods 
should be standardized and harmonized internationally.  
Manufacturers must be made aware that alternative potency testing methods are acceptable to the regulatory 
authorities in the United States if they are scientifically justified and validated. In this case, early and frequent 
communication will ensure that efforts are not lost or directed toward obtaining data that regulators do not consider 
valuable. For example, due to the differences in the current EU and U.S. methods for measuring diphtheria toxoid 
potency, the Vero cell assay for diphtheria toxoid requires additional validation to ensure that it meets all regional 
testing requirements. The use of Vero cells for potency testing is not currently approved in the United States but 
would be considered if the assay was appropriately validated with demonstration of equivalence to the current NIH 
test. However, it was noted that the current NIH test uses far fewer animals than the WHO/Ph. Eur. multiple-dilution 
assays. Use of the serological assay for diphtheria vaccine would have much lower impact in this case. Workshop 
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participants questioned the need for this additional testing and validation and noted that validation of refinement 
alternatives for potency testing of other vaccines remains a higher priority. 
Additional activities that could further advance acceptance and broader use of alternative methods include the 
following: 
x Encouraging broader access to information that describes vaccine potency testing methods that have been 
successfully implemented to reduce, refine, and replace the use of animals (e.g., open online access to U.S. 
Pharmacopeia [USP] and Ph. Eur. monographs, WHO manual of laboratory methods [now in press])  
x Recognizing that, although international harmonization of methods and procedures for validation is considered 
important, product-specific validation may still be necessary 
x Recognition of who is the driving force for decisions on changes to required testing, understanding that regulators 
can facilitate the change, but this needs to be a joint effort between manufacturers and regulators 
9. Reduction and refinement methods: extrapolating veterinary vaccine potency testing to human vaccines 
and vice versa
In April 2004, the USDA Center for Veterinary Biologics (CVB) issued notice No. 04-09 (9 CFR 117.4e). The 
following wording may be added to all codified potency tests that are conducted by administering viable virus, 
bacteria, or a bacterial toxin to animals in a dose that is expected to be lethal: 
Moribund animals exhibiting clinical signs consistent with the expected disease pathogenesis that are 
unable to rise or move under their own power may be humanely euthanized and considered as deaths as 
outlined in 9 CFR 117.4. In the case of the rabies animals exhibiting paresis, paralysis, and/or convulsions 
may be humanely euthanized and considered as deaths as outlined in 9 CFR 117.4. 
Workshop participants recommended that the U.S. FDA-CBER provide similar guidance on moribund 
euthanasia. This guidance could have a significant and immediate impact on refining animal use for human vaccine 
potency challenge testing. 
Ideally, harmonized and globally accepted guidance on humane endpoints should be developed that could apply 
to potency testing for both human and veterinary vaccines, recognizing that specific humane endpoints must be 
tailored for each vaccine. Because the same approaches should be taken for veterinary and human vaccines, there is 
an obvious need for consultation between these groups. For example, although serological approaches to veterinary 
toxoid vaccines are similar to those for human vaccines, the license-specific tests might differ. Therefore, continued 
interaction between groups is necessary to ensure that every benefit is realized.
10. Other issues to be addressed to facilitate the reduction and refinement of animals in human vaccine 
potency testing 
Participants also discussed the advantages offered by the consistency approach to manufacturing control. They 
agreed that the confidence gained internationally with a product that has a proven consistency record over time 
should lead to a reduced demand for additional animal testing by NCLs. The consistency approach implies the use 
of a set of parameters (e.g., antigen content, antigen integrity, purity, etc.) to constitute a product profile that can 
replace current release tests. The product profile is established to satisfy regulators at the time of licensing and is 
monitored throughout production under a strict quality system. The product profile ensures that each lot released is 
similar to a manufacturer-specific vaccine of proven clinical efficacy and safety with respect to all characteristics 
agreed upon at the licensing stage between manufacturer and regulator [73]. 
11. Discussion 
The International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in 
Vaccine Potency and Safety Testing: State of the Science and Future Directions was the first workshop in the United 
States focused on alternative methods to bring together regulators, manufacturers, and experts involved in both 
human and veterinary vaccine development and licensing. Participants shared a goal of reviewing the current state 
of the science and identifying opportunities for future progress in implementation of 3R alternatives in vaccine 
potency and safety testing. Several other recent symposia and workshops have been convened in an attempt to 
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further the science of the 3Rs, for example, when using animals for quality control of vaccines. These symposia 
addressed various aspects of (1) promoting and facilitating the use of non-animal methods for the quality control of 
either human or veterinary vaccines and (2) increasing the understanding and implementation of the consistency 
approach to the manufacturing of human and veterinary vaccines.  
The following international symposia were dedicated to finding new ways to advance the development and 
implementation of alternative methods for the quality control of human or veterinary vaccines: 
x Alternatives to Animal Testing: New Approaches in the Development and Control of Biologicals; Dubrovnik, 
Croatia (April 2008) 
x The Consistency Approach for Quality Control of Vaccines – A Strategy to Improve Quality Control and 
Implement the 3Rs; Brussels, Belgium (January 2010) 
x Practical Alternatives to Reduce Animal Testing in Quality Control of Veterinary Biologicals in the Americas; 
Buenos Aires, Argentina (February 2010) 
In the current workshop, participants highlighted the need for basic scientific research, product-specific research 
and validation efforts, and regulatory harmonization to advance the development, validation, and implementation of 
alternative methods to reduce and refine (less pain and distress) the use of animals in lot release potency testing for 
human vaccines. Specific recommendations were considered necessary to address scientific knowledge gaps that 
must be filled in order to advance the development of reduction and refinement alternatives. An increase in the basic 
understanding of antigens and antigenic properties as it pertains to vaccines would facilitate development of 
serological methods. Better defining the processes and/or product specific information associated with current 
potency tests (e.g., Vero Cell assays for Diphtheria toxoid; the RFFIT for rabies vaccine) could improve the 
likelihood that refinement alternatives are developed. Identifying the specific signs of disease progression for each 
vaccine target would facilitate defining earlier more humane endpoints that could routinely be used to terminate 
studies.  
More open access should be provided to methods and information that are currently restricted (e.g., 
pharmacopoeial monographs). Greater accessibility would increase the likelihood of implementing available 
alternatives. This could also be achieved by increasing interactions and dissemination of information between 
regulators, manufacturers, and the scientific community. This workshop was also successful in setting the stage for a 
series of future workshops on the identified priority vaccines. Based upon the general scientific literature and the 
presentations at the workshop, there is broad international consensus to reduce, refine and replace the use of animal 
for both human and veterinary vaccine potency testing. Implementation of the workshop recommendations is 
expected to advance alternative methods for vaccine potency testing that will benefit animal welfare while ensuring 
continued safety and efficacy of vaccines for human and veterinary use. 
12. Conclusions 
The human vaccine reduction and refinement alternatives session successfully summarized the current status of 
potency testing of human vaccines and identified the critical vaccines for which priority should be given to develop 
alternative tests for currently used in vivo challenge or toxin neutralization tests. This will allow prioritization of the 
necessary research, development, and validation work to expedite potency testing with earlier, more humane 
endpoints and using fewer animals. It was recognized that increasing our knowledge base of each antigen and 
building on current knowledge of existing serological methods is the most expeditious way to advance the use of 
serological methods in vaccine potency testing. Workshop participants agreed that there is no logical or scientific 
rationale for requiring death as an endpoint during the conduct of a vaccine challenge potency test. Participants also 
provided valuable recommendations for advancing the identification, validation, and implementation of the use of 
humane endpoints in vaccine potency testing. Increasing our understanding of the causes of variability in potency 
tests will also facilitate reduction in the number of animals required to document potency while maintaining the 
statistical power of the assay. Finally, the workshop participants recognized that international harmonization, with 
the continued interaction of the global vaccine community, human and veterinary, is the key to advancing the use of 
3R alternatives in vaccine potency testing. 
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